Skip to main content
Erschienen in: Pituitary 6/2023

21.09.2023

Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis

verfasst von: Huy Gia Vuong, Ian F. Dunn

Erschienen in: Pituitary | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Sparsely granulated somatotroph adenoma/tumor (SGST) is thought to be more clinically aggressive than densely granulated somatotroph adenoma/tumor (DGST). However, the literature is not entirely consistent as to the disparate demographic and behavioral features of these subtypes. In this study, we conducted a meta-analysis to further clarify the demographic, clinicopathological, prognostic, and molecular characteristics of SGST versus DGST.

Methods

We accessed two electronic databases to search for potential data. Pooled estimates of odds ratio (OR), mean difference (MD), and corresponding 95% confidence interval (CI) were calculated using the random-effect model.

Results

SGST was associated with younger patient age and lower male-to-female ratio (p < 0.001) compared to DGST. Clinically, SGST had larger tumor size and high rate of cavernous sinus and suprasellar extension (p < 0.001) than DGST. During postoperative follow-up, SGST was associated with a lower endocrinological remission rate (OR 0.60; 95% CI 0.40 to 0.90; p = 0.01) and a poorer response rate to SRL (OR 0.16; 95% CI 0.08–0.35; p < 0.001) in comparison to DGST. The prevalence of GSP mutations was significantly lower in SGST (OR 0.36; 95% CI 0.17 to 0.79; p = 0.01).

Conclusion

SGST and DGST were demographically, clinicopathologically, and molecularly different from each other with the former associated with adverse treatment outcomes and poor response to medical therapy. There are still gaps in translational studies that could help us better understand the behavior of these tumors and identify potential targets in the treatment of sparsely granulated tumors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243 CrossRefPubMed Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243 CrossRefPubMed
2.
Zurück zum Zitat Yamada S, Aiba T, Sano T et al (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1):20–27 PubMed Yamada S, Aiba T, Sano T et al (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1):20–27 PubMed
3.
Zurück zum Zitat Obari A, Sano T, Ohyama K et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91 CrossRefPubMed Obari A, Sano T, Ohyama K et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91 CrossRefPubMed
4.
Zurück zum Zitat Melmed S, Braunstein GD, Horvath E, Ezrin C, Kovacs K (1983) Pathophysiology of acromegaly. Endocr Rev 4(3):271–290 CrossRefPubMed Melmed S, Braunstein GD, Horvath E, Ezrin C, Kovacs K (1983) Pathophysiology of acromegaly. Endocr Rev 4(3):271–290 CrossRefPubMed
5.
Zurück zum Zitat Bakhtiar Y, Hirano H, Arita K et al (2010) Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol 163(4):531–539 CrossRefPubMed Bakhtiar Y, Hirano H, Arita K et al (2010) Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol 163(4):531–539 CrossRefPubMed
6.
Zurück zum Zitat Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490–498 CrossRefPubMed Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490–498 CrossRefPubMed
7.
Zurück zum Zitat Kato M, Inoshita N, Sugiyama T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59(3):221–228 CrossRefPubMed Kato M, Inoshita N, Sugiyama T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59(3):221–228 CrossRefPubMed
8.
Zurück zum Zitat Mori R, Inoshita N, Takahashi-Fujigasaki J et al (2013) Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013:723432 CrossRefPubMedPubMedCentral Mori R, Inoshita N, Takahashi-Fujigasaki J et al (2013) Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013:723432 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O (2013) Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168(4):491–499 CrossRefPubMed Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O (2013) Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168(4):491–499 CrossRefPubMed
10.
Zurück zum Zitat Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18(3):326–334 CrossRefPubMed Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18(3):326–334 CrossRefPubMed
11.
Zurück zum Zitat Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–6295 CrossRefPubMed Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–6295 CrossRefPubMed
12.
Zurück zum Zitat Sarkar S, Chacko AG, Chacko G (2014) An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir. 156(12):2221–2230 ( discussion 2230) CrossRefPubMed Sarkar S, Chacko AG, Chacko G (2014) An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir. 156(12):2221–2230 ( discussion 2230) CrossRefPubMed
13.
Zurück zum Zitat Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96–102 CrossRef Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96–102 CrossRef
14.
Zurück zum Zitat Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148 CrossRefPubMed Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148 CrossRefPubMed
15.
Zurück zum Zitat Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558 CrossRefPubMed Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558 CrossRefPubMed
16.
Zurück zum Zitat Vuong HG, Dunn IF (2023) The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis. Endocrine Vuong HG, Dunn IF (2023) The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis. Endocrine
17.
Zurück zum Zitat Dehghani M, Davoodi Z, Bidari F et al (2021) Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study. BMC Endocr Disord 21(1):186 CrossRefPubMedPubMedCentral Dehghani M, Davoodi Z, Bidari F et al (2021) Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study. BMC Endocr Disord 21(1):186 CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Durmuş ET, Atmaca A, Kefeli M et al (2022) Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res 67:101502 CrossRefPubMed Durmuş ET, Atmaca A, Kefeli M et al (2022) Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res 67:101502 CrossRefPubMed
19.
Zurück zum Zitat Heng L, Liu X, Jia D et al (2021) Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas. Clin Endocrinol 95(1):134–142 CrossRef Heng L, Liu X, Jia D et al (2021) Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas. Clin Endocrinol 95(1):134–142 CrossRef
20.
Zurück zum Zitat Iacovazzo D, Carlsen E, Lugli F et al (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241–250 CrossRefPubMed Iacovazzo D, Carlsen E, Lugli F et al (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241–250 CrossRefPubMed
21.
Zurück zum Zitat Kasuki L, Wildemberg LE, Neto LV, Marcondes J, Takiya CM, Gadelha MR (2013) Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol 169(2):217–223 CrossRefPubMed Kasuki L, Wildemberg LE, Neto LV, Marcondes J, Takiya CM, Gadelha MR (2013) Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol 169(2):217–223 CrossRefPubMed
22.
Zurück zum Zitat Park YW, Kang Y, Ahn SS et al (2020) Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary 23(6):691–700 CrossRefPubMed Park YW, Kang Y, Ahn SS et al (2020) Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary 23(6):691–700 CrossRefPubMed
23.
Zurück zum Zitat Soukup J, Cesak T, Hornychova H et al (2021) Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity. Histopathology 79(3):406–415 CrossRefPubMed Soukup J, Cesak T, Hornychova H et al (2021) Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity. Histopathology 79(3):406–415 CrossRefPubMed
24.
Zurück zum Zitat Swanson AA, Erickson D, Donegan DM et al (2021) Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary 24(2):192–206 CrossRefPubMed Swanson AA, Erickson D, Donegan DM et al (2021) Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary 24(2):192–206 CrossRefPubMed
25.
Zurück zum Zitat Tang Y, Xie T, Wu S et al (2021) Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas. Endocrine 74(2):375–386 CrossRefPubMed Tang Y, Xie T, Wu S et al (2021) Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas. Endocrine 74(2):375–386 CrossRefPubMed
26.
Zurück zum Zitat Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169(4):391–400 CrossRefPubMed Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169(4):391–400 CrossRefPubMed
29.
Zurück zum Zitat Florio T, Morini M, Villa V et al (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144(4):1574–1584 CrossRefPubMed Florio T, Morini M, Villa V et al (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144(4):1574–1584 CrossRefPubMed
30.
Zurück zum Zitat Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24(5):238–246 CrossRefPubMed Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24(5):238–246 CrossRefPubMed
31.
Zurück zum Zitat Córdoba-Chacón J, Gahete MD, Duran-Prado M et al (2010) Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci 67(7):1147–1163 CrossRefPubMed Córdoba-Chacón J, Gahete MD, Duran-Prado M et al (2010) Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci 67(7):1147–1163 CrossRefPubMed
32.
Zurück zum Zitat Durán-Prado M, Gahete MD, Martínez-Fuentes AJ et al (2009) Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 94(7):2634–2643 CrossRefPubMed Durán-Prado M, Gahete MD, Martínez-Fuentes AJ et al (2009) Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 94(7):2634–2643 CrossRefPubMed
33.
Zurück zum Zitat Sano T, Rong QZ, Kagawa N, Yamada S (2004) Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–132 CrossRefPubMed Sano T, Rong QZ, Kagawa N, Yamada S (2004) Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–132 CrossRefPubMed
34.
Zurück zum Zitat Qian ZR, Sano T, Yoshimoto K et al (2007) Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20(12):1269–1277 CrossRefPubMed Qian ZR, Sano T, Yoshimoto K et al (2007) Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20(12):1269–1277 CrossRefPubMed
35.
Zurück zum Zitat Spada A, Arosio M, Bochicchio D et al (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71(6):1421–1426 CrossRefPubMed Spada A, Arosio M, Bochicchio D et al (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71(6):1421–1426 CrossRefPubMed
36.
Zurück zum Zitat Efstathiadou ZA, Bargiota A, Chrisoulidou A et al (2015) Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. Pituitary 18(6):861–867 CrossRefPubMed Efstathiadou ZA, Bargiota A, Chrisoulidou A et al (2015) Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. Pituitary 18(6):861–867 CrossRefPubMed
37.
Zurück zum Zitat Mazal PR, Czech T, Sedivy R et al (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 20(4):163-171 Mazal PR, Czech T, Sedivy R et al (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 20(4):163-171
Metadaten
Titel
Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis
verfasst von
Huy Gia Vuong
Ian F. Dunn
Publikationsdatum
21.09.2023
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 6/2023
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-023-01353-0

Weitere Artikel der Ausgabe 6/2023

Pituitary 6/2023 Zur Ausgabe

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.